Renal cell carcinoma treatment

Preoperative thymic output and T cell repertoire diversity are associated with recurrence after nephrectomy for localized renal cell carcinoma

Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency

This study creates a mouse model of VHL-/-TSC1-/- ccRCC, identifies metabolic and redox reprogramming, and highlights NRF2 as a therapeutic target.

TFE3 fusions drive expression of CD44 and SPP1 in Translocation Renal Cell Carcinoma

The paper shows TFE3 fusions upregulate CD44 and SPP1 in tRCC, with potential therapeutic implications.

Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases

The paper identifies recurrent copy-number alterations in RCC brain metastases and shows their association with poor prognosis and metastatic potential across multiple cancers.

Clear cell renal cell carcinoma consensus transcriptomic programs reveal converging trajectories towards aggressive disease

The paper identifies 17 consensus transcriptomic programs in ccRCC using NMF and links them to cellular sources and clinical outcomes, revealing converging trajectories toward aggressive disease.

Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

Decoding the Plasma Proteomic Landscape of Clear Cell Renal Cell Carcinoma Reveals Diagnostic and Prognostic Liquid Biopsy Biomarkers

This paper identifies plasma proteomic biomarkers for diagnosing and prognosticating clear cell renal cell carcinoma through longitudinal mass spectrometry profiling.

Survivin as a Multifaceted Oncogenic Driver and Therapeutic Target in Renal Cell Carcinoma

This study identifies survivin as a key oncogenic driver in renal cell carcinoma, showing its roles in cell cycle, migration, and mitochondrial function, and suggests it as a therapeutic target.

Absolute quantitative proteomics guides patient-stratified drug repurposing in clear cell and papillary renal cell carcinoma.

This paper uses absolute quantitative proteomics to identify patient-specific drug repurposing strategies for clear cell and papillary renal cell carcinoma.

Single-cell gene programs define subtype identity and metastatic trajectories in renal cell carcinoma

This study identifies 59 gene expression programs in RCC that reveal subtype identity and metastatic trajectories, including a metastatic signature linked to poor clinical outcomes.

Site-Dependent Decoupling of Drug-Biomarker Associations in Clear Cell Renal Cell Carcinoma Revealed by Functional Profiling of Patient-Derived Cell Models

The paper identifies site-dependent drug-biomarker associations in ccRCC using patient-derived models and multi-omic data, revealing discrepancies between genomic predictions and functional drug responses.

Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma

This study identifies TRAIL as a synthetic essentiality in VHL-deficient ccRCC, showing its regulation by HIF2 and its role in cell proliferation through the p38 MAPK pathway, suggesting a combination therapy strategy.

Not All Predictors Of RCC Clusters Are The Same: An individual sample predictive model to classify patients with metastatic renal cell carcinoma

The paper develops a machine learning model to predict treatment response in RCC patients using individual-sample RNAseq data, finding that standardization methods affect cluster predictions.

Single-Cell Multi-Omics Dissection of Malignant Evolutionary Mechanisms and Construction of a Prognostic Model for Clear Cell Renal Cell Carcinoma

The paper integrates single-cell multi-omics data to identify prognostic markers and mechanisms of progression in clear cell renal cell carcinoma.

Differential Transcript Usage Reveals Isoform-Level Remodeling of Tumor Biology in Clear Cell Renal Cell Carcinoma

The paper identifies isoform-level changes in ccRCC using DTU analysis, revealing subgroups with distinct survival outcomes and potential biomarkers.

Sexually dimorphic effects of mutations in ccRCC driver genes in renal proximal tubule cells

The paper investigates sex-specific effects of Vhl and Vhl/Pbrm1 mutations in renal proximal tubule cells, revealing differences in lipid droplet accumulation and clonal expansion between males and females.

Profilin-1 Promotes Chromophobe Renal Cell Carcinoma Malignancy

This study identifies Profilin-1 as a driver of chromophobe renal cell carcinoma progression by promoting proliferation, invasion, and resistance to oxidative stress.

Fibroblast-derived Collagen VI shapes the structure and function of the tumor-immune microenvironment in clear cell renal cell carcinoma

This study identifies collagen VI as a key ECM component in ccRCC stroma, showing its role in shaping tumor structure, function, and immune response, with implications for TKI therapy.

VHL synthetic lethality screens uncover CBF-beta as a negative regulator of STING

The paper identifies CBF-beta as a negative regulator of STING through synthetic lethality screens in VHL-null ccRCC cells, showing its role in type I interferon signaling and tumor growth.

A minimal transcriptomic signature predicts intravascular tumor extension in renal cell carcinoma

The paper identifies a 13-gene transcriptomic signature that predicts intravascular tumor extension in renal cell carcinoma using RNA sequencing data from multiple cohorts.

Convergent genomic and molecular features predict risk of metachronous metastasis in clear cell renal cell carcinoma

This study identifies genomic and transcriptomic features on chromosome 1p associated with metachronous metastasis risk in ccRCC and develops a predictive model.

Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancer

The paper identifies an IFN response-high epigenetic program linked to BAP1 deficiency in kidney cancer using single nucleus ATAC sequencing across multiple cohorts.

Transcriptomic evaluation of immune-infiltrated patient-derived tumor organoids as preclinical models in renal cell carcinoma

The paper evaluates immune-infiltrated patient-derived tumor organoids as preclinical models for renal cell carcinoma, showing they retain immune signatures and hypoxic signaling relevant to the original tumors.

Integrative transcriptomic profiling of the phosphatome identifies DUSP15 as a chromophobe renal cell carcinoma-selective epithelial biomarker associated with an immune-metabolic tumour state

The paper identifies DUSP15 as a chRCC-selective biomarker through transcriptomic analysis and links it to an immune-metabolic tumor state.

Proteomic characterization of sporadic clear cell renal cell carcinoma reveals a matrix-dense pseudocapsule and heterogeneous tumor subtypes

This study uses proteomics to characterize sporadic ccRCC, identifying a matrix-dense pseudocapsule and five tumor subtypes with distinct biological features.

Seven blood biomarkers are associated with TGF-β and VHL-HIF signaling in patients with clear cell renal cell carcinoma

This study identifies seven blood biomarkers associated with TGF-β and VHL-HIF signaling in ccRCC patients, showing their potential for prognosis and personalized medicine.

Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

CLEC18A interacts with sulfated GAGs and controls clear cell renal cell carcinoma progression

This study identifies CLEC18A as a regulator of clear cell renal cell carcinoma progression by interacting with sulfated GAGs and shows its expression is linked to improved patient survival.

Peroxidasin expression is increased in intratumoural capillaries and in proximal tubular cells adjacent to clear cell renal cell carcinoma.

NSD2 promotes cell durotaxis and drives the transition from PKD to tubulocystic renal cell carcinoma through integrin/FAK/AKT signaling

This study shows NSD2 promotes cell durotaxis and drives the transition from PKD to TCRCC via integrin/FAK/AKT signaling, with implications for targeted therapies.